Genetic correlates of efavirenz hypersusceptibility

AIDS

Volumn 18, Issue 13, 2004, Pages 1781-1785

  Shulman, Nancy S ^a   Bosch, Ronald J ^b   Mellors, John W ^c   Albrecht, Mary A ^d   Katzenstein, David A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Drug resistance; Efavirenz; Hypersusceptibility; Non nucleoside reverse transcriptase inhibitor; Phenotype

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CODON; CONTROLLED STUDY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS; VIRAL GENETICS;

ANTI-HIV AGENTS; GENOTYPE; HIV INFECTIONS; HUMANS; MUTATION; OXAZINES; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; VIRUS REPLICATION;

EID: 4444371619     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409030-00006     Document Type: Article

References (14)

1. Whitcomb JM, Huang W, Limoli K, Raxinos E, Wrin T, Skowton G, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002; 16:F41-F47.
2. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001; 15:1125-1132.
3. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16:F33-F40.
4. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-180.
5. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four anti-retroviral drugs. AIDS 2003; 17:821-830.
6. Skov T, Deddens J, Petersen MR, Endahl L. Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol 1998; 27:91-95.
7. Los Alamos National Laboratory website. Available at: www.lanl. gov. Accessed: June 2003.
8. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:4040-4049.
9. Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004; 279:509-516.
10. Miller MD, Margot NA, Lu B. Effect of baseline nucleoside-associated resistance on response to tenofovir DF (TDF) therapy: integrated analyses of studies 902 and 907. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 24-28 February 2002 [Abstract 43].
11. Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72:162-165.
12. Paxinos E, Sartoris M, Dawson K, Hellmann N, Petropoulos C, Richman DD, et al. Natural variation in susceptibility to non-nucleoside reverse transcriptase inhibitors predates drug availability. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [Abstract 1243].
13. Hellmann N, Johnson P, Petropoulos C. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSense HIV. In: 3rd International Workshop on HIV Drug Resistance and Treatment Strategies. San Diego, CA, 23-26 June 1999 [Abstract 51].
14. Leigh Brown AJ, Frost SD, Good B, Daar ES, Simon V, Markowitz M, et al. Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol 2004; 78:2242-2246.